Three patients (27.3%) experienced five AEs, leading to dose modification or interruption of study medication: one in the simlukafusp alfa 15/20 mg (grade 2 embolism) and two in the simlukafusp alfa 10 mg plus atezolizumab (one had grade 3 aspartate aminotransferase increased, grade 3 alanine aminotransferase increased, and grade 1 bronchitis, and one had a grade 2 IRR) cohorts. The gene discussed is GPT; the disease is bronchitis.